Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells.
Anticancer activity of extracellular nucleotides has been investigated in many types of cancer. Herein, the effects of extracellular nucleotides and the receptor profile for these nucleotides on prostate cancer (PCa) were elaborated.



PCa cell lines representing different stages of PCa were used. The effects of ATP and adenosine on PCa growth and migration on different extracellular matrix proteins were examined by MTT and wound-healing assays. Purinergic receptor profiling was carried out by reverse transcription-polymerase chain reaction (RT-PCR).



A growth-inhibitory effect of ATP and adenosine was observed on all PCa cell lines tested. Several ATP-recognized P2 receptors and adenosine receptors were commonly expressed in PCa cell lines. Neither ATP nor adenosine had any significant effect on PCa migration.



ATP and adenosine had an antiproliferative effect on PCa cells without affecting their motility, indicating their potential as a novel therapy for PCa.
Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.
Kornkamon
K
Lertsuwan
Laboratory for Cancer Ontogeny and Therapeutics, Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, DE, U.S.A.
Wachen
W
Peters
Laboratory for Cancer Ontogeny and Therapeutics, Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, DE, U.S.A.
Lindsay
L
Johnson
Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, Thailand.
Jomnarong
J
Lertsuwan
Laboratory for Cancer Ontogeny and Therapeutics, Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, DE, U.S.A.
Irene
I
Marwa
Laboratory for Cancer Ontogeny and Therapeutics, Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, DE, U.S.A. rasikes@udel.edu.
Robert A
RA
Sikes
D000241:Adenosine / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000494:pharmacology*; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D058913:Purinergic Agonists / Q000494:pharmacology*; D011983:Receptors, Purinergic / Q000096:biosynthesis*
D058913:Purinergic Agonists; D011983:Receptors, Purinergic; D000255:Adenosine Triphosphate; D000241:Adenosine
ATP; adenosine; growth inhibition; prostate cancer